Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Improving TTD and supporting patient advocacy in CTCL

Chalid Assaf • 14 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, Germany, highlights key areas of research in the field of cutaneous T-cell lymphoma (CTCL), in particular focusing on the need to reduce the time to diagnosis (TTD) and the importance of patient advocacy. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Chalid Assaf

2:15
Updates on the brentuximab vedotin for CTCL
Chalid Assaf • 14 Oct 2021
3:21
Low-dose gemcitabine for advanced CTCL
Chalid Assaf • 14 Oct 2021
2:46
ALCANZA: brentuximab vedotin for CTCL
Chalid Assaf • 14 Oct 2021
1:26
Chlormethine gel for mycosis fungoides
Chalid Assaf • 14 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals